Have a feature idea you'd love to see implemented?
Let us know!
GRCE Grace Therapeutics Inc.
Price (delayed)
$3.7
Market cap
$37.52M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.01
Enterprise value
$22.36M
Highlights
The debt has shrunk by 100% YoY
The EPS has surged by 81% year-on-year and by 11% since the previous quarter
Grace Therapeutics's quick ratio has shrunk by 71% YoY and by 23% QoQ
The company's equity fell by 16% YoY and by 5% QoQ
Key stats
What are the main financial stats of GRCE
Market
Valuations
Earnings
Shares outstanding
10.14M
Market cap
$37.52M
Enterprise value
$22.36M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.67
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Net income
-$11.61M
EBIT
-$15.08M
EBITDA
-$15.07M
Free cash flow
-$11.84M
Per share
Balance sheet
Liquidity
EPS
-$1.01
EPS diluted
-$1.01
Free cash flow per share
-$1.03
Book value per share
$5.54
Revenue per share
$0
TBVPS
$1.4
Total assets
$65.35M
Total liabilities
$9.22M
Debt
$0
Equity
$56.13M
Working capital
$13.39M
Debt to equity
0
Current ratio
6.01
Quick ratio
5.83
Net debt/EBITDA
1.01
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-16.3%
Return on equity
-19.2%
Return on invested capital
-2,246.4%
Return on capital employed
-24.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GRCE stock price
How has the Grace Therapeutics stock price performed over time
Intraday
2.78%
1 week
-8.87%
1 month
10.45%
1 year
64.44%
YTD
28.03%
QTD
23.33%
Financial performance
How have Grace Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$16.1M
Net income
-$11.61M
Gross margin
N/A
Net margin
N/A
Grace Therapeutics's net income has soared by 71% YoY
GRCE's operating income has soared by 67% year-on-year but it is down by 20% since the previous quarter
Growth
What is Grace Therapeutics's growth rate over time
Valuation
What is Grace Therapeutics stock price valuation
P/E
N/A
P/B
0.67
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has surged by 81% year-on-year and by 11% since the previous quarter
The stock's P/B is 34% above its last 4 quarters average of 0.5 but 33% below its 5-year quarterly average of 1.0
The company's equity fell by 16% YoY and by 5% QoQ
Efficiency
How efficient is Grace Therapeutics business performance
Grace Therapeutics's ROIC has plunged by 95% from the previous quarter but it has increased by 47% YoY
The ROA has soared by 65% YoY but it has contracted by 6% from the previous quarter
The ROE has soared by 65% YoY but it has contracted by 6% from the previous quarter
Dividends
What is GRCE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GRCE.
Financial health
How did Grace Therapeutics financials performed over time
Grace Therapeutics's quick ratio has shrunk by 71% YoY and by 23% QoQ
The company's current ratio has shrunk by 71% YoY and by 24% QoQ
The debt is 100% lower than the equity
The debt has shrunk by 100% YoY
The company's equity fell by 16% YoY and by 5% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.